Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence.

ACS pharmacology & translational science·2023
Same author

Aging-related modifications to G protein-coupled receptor signaling diversity.

Pharmacology & therapeutics·2020
Same author

Reply to Schierwagen et al.: β-Arrestins in liver disease.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

SnapShot: β-Arrestin Functions.

Cell·2020
Same author

β-Arrestin2 is a critical component of the GPCR-eNOS signalosome.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Conformational Sensors and Domain Swapping Reveal Structural and Functional Differences between β-Arrestin Isoforms.

Cell reports·2019
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Refining efficacy: exploiting functional selectivity for drug discovery.

Diane Gesty-Palmer1, Louis M Luttrell

  • 1Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Advances in Pharmacology (San Diego, Calif.)
|September 13, 2011
PubMed
Summary
This summary is machine-generated.

Ligands can selectively activate specific signaling pathways of G protein-coupled receptors (GPCRs), a phenomenon known as functional selectivity. This allows for tailored therapeutic effects by biasing receptor activity towards desired outcomes, minimizing side effects.

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Related Experiment Videos

Last Updated: May 29, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Area of Science:

  • Pharmacology
  • Biochemistry
  • Molecular Biology

Background:

  • G protein-coupled receptors (GPCRs) were initially modeled as existing in simple 'off' and 'on' states.
  • Emerging evidence shows GPCRs exist in multiple conformations, with ligands dictating which active states predominate.
  • Functional selectivity, or ligand bias, describes a ligand's ability to activate a subset of a receptor's signaling pathways.

Purpose of the Study:

  • To explore the concept of functional selectivity in GPCR signaling.
  • To highlight the type 1 parathyroid hormone receptor (PTH(1)R) as a model system for studying biased agonism.
  • To investigate the potential of biased ligands for developing therapeutics with improved efficacy and reduced side effects.

Main Methods:

  • Review of existing literature on GPCR activation models and functional selectivity.
  • Analysis of studies utilizing the type 1 parathyroid hormone receptor (PTH(1)R) as a model.
  • In vivo characterization of biased PTH(1)R ligands and their downstream signaling effects.

Main Results:

  • GPCRs dynamically sample multiple conformations, enabling biased signaling.
  • The PTH(1)R system demonstrates that biased ligands can selectively activate G(s) or G(q/11) pathways, independently of arrestin-dependent pathways.
  • In vivo studies confirm the ability of biased ligands to modulate PTH actions, separating anabolic from catabolic effects.

Conclusions:

  • Functional selectivity represents a qualitative shift in GPCR signaling modulation.
  • Biased ligands offer a promising strategy for developing novel therapeutics by precisely targeting specific signaling pathways.
  • Exploiting ligand bias in GPCRs, like the PTH(1)R, could lead to drugs with enhanced therapeutic benefits and fewer adverse effects.